ClinicalTrials.gg
TerminatedNCT06140329Updated Mar 14, 2025

Natural History of Autosomal Dominant Optic Atrophy (ADOA), Caused by OPA1 Mutation

An observational study in Autosomal Dominant Optic Atrophy, Optic Atrophy, Autosomal Dominant and Optic Atrophies, Hereditary, sponsored by PYC Therapeutics. Terminated at 7 sites in 6 countries. Open to participants aged 8 Years and older. Per ClinicalTrials.gov, last updated 2025-03-14.

Sponsored by PYC Therapeutics · Observational

How we know

Why this study was terminated
The study was terminated due to low participant enrolment and to accommodate PYC's future interventional study.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1
Ages
8 Years and older
Sex
All
01

Study summary

The purpose of this study is to characterize the disease progression of confirmed OPA1 mutation-associated autosomal dominant optic atrophy (ADOA) by evaluating the changes in ocular structural and functional outcomes.

Read the detailed description

This is a multi-center, longitudinal, prospective, observational natural history study of patients with confirmed OPA1 mutation (haploinsufficiency) associated ADOA. The study will be conducted at up to 10 sites across the United States, Australia and Europe.

Each participant's medical record will be reviewed for historical information, and clinical data will be recorded in a secure database. Natural history data will be collected prospectively and will include ophthalmic exams, imaging studies and electrophysiological testing. Assessments will be conducted as described in this protocol approximately every 3 months in the first year and every 6 months in the second year of the study after each participant's baseline visit

02

Conditions studied

  • Autosomal Dominant Optic Atrophy
  • Optic Atrophy, Autosomal Dominant
  • Optic Atrophies, Hereditary
  • Kjer Optic Atrophy
03

In context

Lead sponsor

PYC Therapeutics is the lead sponsor of 8 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
8 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population will consist of approximately 40 participants (80 eyes) with a genetically confirmed OPA1 mutation.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants and/or their parent(s)/guardian(s) must have given written before any study-related activities are carried out and must be able to understand the full nature and purpose of the trial, including possible risks and adverse effects. Assent, where appropriate, will be obtained according to institutional guidelines.
  • Males and females, 8 years of age and above.
  • Have a clinical diagnosis of OPA1 mutation (haploinsufficiency) associated ADOA.
  • No other ocular pathology.
  • Patients with best-corrected visual acuity (BCVA) of between 20/40 (70 Early Treatment of Diabetic Retinopathy Study [ETDRS] letters) and 20/160 (39-43 ETDRS letters)
  • Willing and able to comply with all study assessments and adhere to the protocol schedule and restrictions.
  • For sites performing the Detection of apoptosis in retinal cells (DARC) procedure, and in volunteers ≥ 12 years only:

    1. Female volunteers must:

      I. Be of non- at least 6 weeks before the screening visit or (where postmenopausal is defined as no menses for 12 months without an alternative medical cause), or

      II. If of childbearing potential, must:

      • Have a negative pregnancy test at the screening visit and prior to each administration of ANX776, and
      • Agree not to attempt to become pregnant or donate ova from signing the consent form until at least 30 days after the last dose of ANX776, and
      • Agree to use adequate (defined as the use of a condom by the male partner combined with the use of a highly effective method of contraception from one month prior to screening until at least 30 days after the last dose of ANX776, if not exclusively in a same-sex relationship or abstinent as a committed lifestyle.
    2. Male volunteers must:

      • Agree not to donate sperm from signing the consent form until at least 90 days after the last dose of ANX776, and
      • If engaging in sexual intercourse with a female partner who could become pregnant, agree to use adequate contraception (defined as the use of a condom combined with the use of a highly effective method of contraception) from signing the consent form until at least 90 days after the last dose of study drug.

Exclusion criteria

Exclusion Criteria:

  • Participant has a known allergy to ANX776 or any of its .
  • Have any uncontrolled systemic disease that, in the opinion of the Investigator, would preclude participation in the study, which includes but is not limited to, infection, uncontrolled elevated blood pressure, cardiovascular disease, or glycemic control issues, or any other medical condition that may put the participant at risk due to study procedures. Note: comorbidities relevant to the pathogenesis of OPA1 associated ADOA (including hearing loss, peripheral neuropathy, myopathy, and ataxia) are acceptable.
  • Have mutations in genes that cause ADOA, other than OPA1 (for example in case of dominant negative ADOA) and ADOA Plus.
  • Within 3 months prior to Baseline (Visit 2), have undergone any vitreoretinal surgery (scleral buckle, pars plana vitrectomy, retrieval of a dropped nucleus or intraocular lens, radial optic neurotomy, sheathotomy, cyclodestructive procedures or multiple filtration surgeries [2 or more]) or any other ocular surgery.
  • Have ocular media opacity or poor pupillary dilation prohibiting quality ophthalmic evaluation or photography, as assessed by the Investigator.
  • Have used any drug or device within 90 days or 5 estimated half-lives of Visit 2, whichever is longer, or plan to participate in another study of a drug or device during the study period. Participation in observational trials is allowable based on Investigator discretion and consultation with the Medical Monitor. It is assumed that the observational trial evaluations would not interfere with participation in this study.
  • Have received any prior cell or gene therapy for a retinal condition.
  • Have a recent history (\<6 months) of or current excessive recreational drug or alcohol use, in the opinion of the Investigator. Note: excessive alcohol use is defined as regular consumption of > 10 standard drinks per week or > 4 standard drinks per day, where 1 standard drink is defined as 10 grams of pure alcohol.
  • Any other condition or prior therapy that in the opinion of the Investigator would make the volunteer unsuitable for this study, including inability to cooperate fully with the requirements of the study protocol or likelihood of noncompliance with any study requirements.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1 participant (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Best-corrected High Contrast Visual Acuity (HCVA)

    Best-corrected high contrast visual acuity (HCVA) for both distance and near will be evaluated using the ETDRS electronic visual acuity charts and the MNRead acuity chart

    Time frame: Baseline through Year 2

  2. Low Contrast Visual Acuity (LCVA)

    Low contrast visual acuity (LCVA) for both distance and near will be evaluated using the low contrast ETDRS letter chart

    Time frame: Screening through Year 2

  3. Contrast Sensitivity

    Contrast sensitivity recorded using the Pelli-Robson chart

    Time frame: Baseline through Year 2

  4. Color Vision

    Color vision tested using the Hardy Rand Rittler test

    Time frame: Baseline through Year 2

  5. Retinal Thickness

    Change retinal thickness is measured using spectral domain optical coherence tomography (SD-OCT), as measured by the central reading center (SD-OCT), as measured by the central reading center

    Time frame: Baseline through Year 2

  6. Ellipsoid Zone (EZ) Volume

    Change in EZ volume measured using spectral domain optical coherence tomography (SD-OCT), as measured by the central reading center

    Time frame: Baseline through Year 2

  7. Ellipsoid Zone (EZ) Area

    Change in EZ area measured using spectral domain optical coherence tomography (SD-OCT), as measured by the central reading center

    Time frame: Baseline through Year 2

  8. Visual Field Sensitivity

    Visual field sensitivity measured by automated static perimetry

    Time frame: Baseline through Year 2

  9. Multifocal Visual Evoked Potential (mfVEP)

    The waveform of the evoked responses, the latency, and amplitude are analyzed.

    Time frame: Baseline through Year 2

  10. Pregnancy Test

    A urine human chorionic gonadotropin (hCG) pregnancy conducted in all women of childbearing potential (WOCBP) \> 12 years of age at baseline. If a urine test is positive, the DARC procedure will not be performed.

    Time frame: Baseline

  11. DARC (Detection of Apoptosing Retinal Cells)

    The DARC test is conducted using an IV injection of fluorescently labelled Annexin V (called ANX776). Individual stressed and apoptotic retinal cells are visible as white spots on the image for DARC count, which are quantified using a confocal scanning laser ophthalmoscope using the indocyanine green angiography (ICGA) settings.

    Time frame: Baseline through Year 2

  12. Flavoprotein Fluorescence (FPF)

    Functional imaging of mitochondria using Flavoprotein Fluorescence.

    Time frame: Baseline through Year 2

  13. Retinal Abnormalities

    Ultrawide fundus photography is conducted OU to assess retinal abnormalities

    Time frame: Baseline through Year 2

  14. Adverse Events (AEs)

    Frequency of ocular adverse events (AEs)

    Time frame: Screening through Year 2

  15. Genomic Analysis for Study Eligibility

    OPA1 genetic testing at screening visit

    Time frame: Screening

  16. Vital signs

    Vital signs assessments (pulse rate, body temperature, systolic and diastolic blood pressure, and respiratory rate) performed in participants undergoing the DARC assessment only.

    Time frame: Baseline through Year 2

Secondary outcomes

  1. To determine the outcome measures that are associated with ADOA disease progression.

    To understand the disease progression in participants with confirmed OPA1 mutation-associated ADOA determined by changes in structural and functional markers from the primary outcome within the study period.

    Time frame: Baseline through Year 2

Other outcomes

  1. To evaluate the safety of ANX776 in patients ≥ 12 years.

    Incidence, type and severity of treatment-emergent and treatment-related AEs in patients ≥ 12 years. Changes from baseline in vital signs (pulse rate, body temperature, systolic and diastolic blood pressure, and respiration rate) in patients ≥ 12 years.

    Time frame: Baseline through Year 2

07

Study locations

7 sites
  • Bascom Palmer Eye Institute
    Miami, Florida 33136, United States
  • University of Washington
    Seattle, Washington 98104, United States
  • Sydney Eye Hospital
    Sydney, New South Wales 2000, Australia
  • Medical University of Graz
    Graz, Styria, Austria
  • CHU de Rennes
    Rennes, Brittany, France
  • Medizinische Hochschule Hannover
    Hanover, Lower Saxony 30625, Germany
  • Amsterdam University Medical Centers
    Amsterdam, 1105, Netherlands
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2024 to primary completion in Mar 2025, 12 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2023
First posted
Nov 18, 2023
StartActual
Feb 28, 2024
Primary completionActual
Mar 1, 2025
CompletionActual
Mar 10, 2025
Last update
Mar 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06140329
Lead sponsor
PYC Therapeutics
Responsible party
Sponsor
First posted
Nov 18, 2023
Start date
Feb 28, 2024
Primary completion
Mar 1, 2025
Completion
Mar 10, 2025
Last update
Mar 14, 2025

Study contacts

Sreenivasu Mudumba, PhD
study chair · PYC Therapeutics

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion